Project description
Combining genetics and imaging for AD drug discovery
Clinical trials on new drugs against Alzheimer's disease (AD) have failed to show any efficacy in slowing disease progression, underscoring the importance of new therapeutic targets. Towards this goal, the EU-funded MAP-AD project will use autosomal and X chromosome genetic variants to identify novel molecular pathways and putative therapeutic targets. Scientists will decipher the impact of specific genetic variants on gene expression through the analysis of post-mortem brain tissue. Combined with multimodal brain imaging analysis, the genomics information will be applied to correctly enrol patients in clinical trials expediting the development of drugs for the prevention and treatment of AD.
Fields of science
Programme(s)
Funding Scheme
MSCA-IF-GF - Global FellowshipsCoordinator
75013 Paris
France
See on map
Partners (1)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
94305 2004 Stanford
See on map